The city of Rochester, New York, currently has 88 active clinical trials seeking participants for Cancer research studies.
Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases
Recruiting
The goal of this study is to create a data registry to capture clinical, pathologic, and molecular data/outcomes for patients with metastatic colorectal cancer who undergo live donor liver transplantation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Colorectal Cancer Metastatic
Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
Recruiting
The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Lung Cancer
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
Recruiting
This study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
03/28/2024
Locations: University of Rochester, Rochester, New York
Conditions: Lung Cancer
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Breast Cancer